Results 31 to 40 of about 9,510 (271)

Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial. [PDF]

CNS Drugs
Krahn L, Roy A, Winkelman JW, Morse AM, Gudeman J.   +4 more
europepmc   +3 more sources

0835 Improvement of Individual Excessive Daytime Sleepiness Symptoms with Once-Nightly Sodium Oxybate for Narcolepsy [PDF]

SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius, Michael J. Thorpy, Ellen Wermter, Clete A. Kushida, Brian Abaluck, Jennifer Gudeman   +5 more
openalex   +2 more sources

0842 Amelioration of Sleep-Related Eating Disorder After Switching from Twice- to Once-Nightly Oxybate [PDF]

SLEEP
Abstract Introduction In a disproportionality analysis (Merino D, et al. J Clin Med. 2022;11:3890), sodium oxybate (SXB) treatment was associated with sleep-related eating disorder (SRED), a parasomnia characterized by somnambulism and compulsive eating. Immediate-release twice-nightly oxybate (TN-OXB)
Lewis Kass
openalex   +2 more sources

0406 Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) Across Stimulant Use Subgroups: Post-hoc Analyses From the REST-ON Trial [PDF]

Sleep Medicine, 2022
Michael J. Thorpy, Yves Dauvilliers, Thomas Roth, A.M. Morse, Asim Roy, Richard Bogan, David Seiden, Jordan Dubow, Jennifer Gudeman   +8 more
openalex   +2 more sources

Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers

Sleep Medicine, 2022
Richard K Bogan, Michael J Thorpy, John W Winkelman   +2 more
exaly   +2 more sources

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

Neurology and Therapy, 2023
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg, Rogelio Braceras, Wayne Macfadden, Shawn Candler, Jed Black, Chad Ruoff   +5 more
doaj   +1 more source

Efficacy of Topical 5% 5-Fluorouracil and 0.05% Tretinoin and Electrosurgery in the Treatment of Plane Warts: A Randomized Controlled Comparative Trial

Nepal Journal of Dermatology, Venereology & Leprology, 2021
Human papilloma virus (HPV) is capable of causing varieties of dermatological conditions differing in morphology, histopathology and site of occurrence.
Rashmi Singh, Shyam Sundar Pandey
doaj   +3 more sources

Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial

Sleep Medicine
Yves Dauvilliers, Thomas Roth, Richard K Bogan   +2 more
exaly   +2 more sources

‘I love you’: the first phrase detected from dreams [PDF]

Sleep Science, 2022
Objective: Many people have dreams nightly and some maintain consciousness during dreams. Such dreams are referred to as lucid dreams (LD). During dreams, our speech correlates with facial muscle activity, which is hard to decode, but LD could solve this
Michael Raduga
doaj   +1 more source

Foraging movements are density-independent among straw-coloured fruit bats [PDF]

Royal Society Open Science, 2020
Intraspecific competition in large aggregations of animals should generate density-dependent effects on foraging patterns. To test how large differences in colony size affect foraging movements, we tracked seasonal movements of the African straw-coloured
María C. Calderón-Capote, Dina K. N. Dechmann, Jakob Fahr, Martin Wikelski, Roland Kays, M. Teague O'Mara   +5 more
doaj   +1 more source